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Summary The cytotoxic activity and cross-resistance pattern of the novel topoisomerase inhibitortopotecan (Topo) were investigated in ten
cell lines, representing different mechanisms of cytotoxic drug resistance, and in 218 fresh human tumour samples using the fluorometric
microculture cytotoxicity assay (FMCA). Resistance to Topo in the cell lines was associated with expression of the multidrug resistance-
associated protein (MRP), whereas the cell lines with P-glycoprotein (P-gp), topoisomerase 11 and glutathione-associated resistance did not
show decreased sensitivity to the drug. Topo was more active in haematological than in solid tumour samples, but substantial activity was
observed in carcinomas of the ovary and breast, sarcoma and childhood solid tumours. Cross-resistance to standard drugs representing
different mechanisms of action was generally low in patient cells. The effect ofTopo was betterafter longer exposure, butthis time-dependent
effect was largely abolished when adjustment for in vitro exposure was made. Topo showed activity both in proliferative and non-proliferative
cell systems. The results indicate that Topo is insensitive to major mechanisms of resistance except for MRP. Proliferation does not seem to
be necessary for the effect of Topo, and no superiority for protracted dosing schedules was observed. The results also suggest that, for
example, leukaemias, lymphomas, sarcomas and childhood solid tumours may be suitable targets for future phase 11 trials.
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Topotecan (Topo) is a semisynthetic analogue ofcamptothecin, an
alkaloid isolated from certain plant species such as Camptotheca
acuminata. Camptothecin was found to be active against tumour
cells in the National Cancer Institute (NCI) drug screening
programme during the 1960s. Although its supposed mechanism
of action was not clarified until the late 1980s, it was introduced
into clinical trials during the 1970s. However, because of
unexpected toxicity and limited activity in phase II trials further
development of this group of drugs was halted until the more
water-soluble and less toxic camptothecin analogues, among them
Topo, were synthesized (Takimoto and Arbuck, 1996).
Topo is the first cytotoxic drug to be considered for approval for
clinical use with the enzyme topoisomerase I as the probable
target. At physiological pH the lactone form ofTopo is in equilib-
rium with the open ring form, but only the former is active (Wall et
al, 1992). Topoisomerase I is a nuclear enzyme present in all
eucaryotic cell types, and is involved in DNA replication and
repair. The enzyme unwinds the supercoiled double-stranded
DNA by temporarily binding to, and cleaving, one of the strands.
In the presence ofTopo, the complex ofcleaved DNA with topoi-
somerase I is stabilized, inhibiting religation (Takimoto and
Arbuck, 1996). The drug-induced single-strand breaks are
reversible, but as the replication goes on and the moving replica-
tion fork interacts with the drug-enzyme-DNA complex, double-
strand breaks result that are thought to be responsible for the
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cytotoxic effects of Topo (Holm et al, 1989). Inhibition of DNA
replication with, e.g. a DNA polymerase inhibitor that blocks
double-strand break production reduces Topo cytotoxicity (Holm
et al, 1989). Topo is therefore considered to be an S phase-specific
drug, producing preferential toxicity to proliferating cells.
Topo has shown cytotoxic activity against a broad range ofcell
types in vitro. Specific activity has been seen against colorectal,
breast, non-small-cell lung (NSCLC), ovarian and renal cancers
(Burris et al, 1992) and acute lymphocytic leukaemia (Uckun et al,
1995) in a clonogenic assay. In mice bearing human tumour
xenografts Topo showed activity against rhabdomyosarcoma
(Houghton et al, 1995) and central nervous system tumours
(Friedman et al, 1994).
Topo has shown clinical activity in many tumour types, for
example ovarian carcinoma (Gore et al, 1996), NSCLC (Perez-
Solar et al, 1996) and leukaemia (Kantarjian et al, 1993; Rowinsky
et al, 1994).
The mechanisms possibly responsible for resistance against
Topo have been studied in various cell lines in vitro. The results
from these studies are not conclusive but have indicated that resis-
tance may be mediated by lowered levels and decreased sensitivity
ofthe target enzyme (topoisomerase I) (Tan et al, 1989; Eng et al,
1990; Sorensen et al, 1995) and decreased drug accumulation
unrelated to known mechanisms (Yang et al, 1995). Resistance
may also, at least partly, be explained by sensitivity to P-glyco-
protein 170 (P-gp)-mediated transport, although to a considerably
lesser extent than known P-gp substrates (Hendricks et al, 1992;
Mattem et al, 1993). An association between the heat shock
protein hsp70 and decreased Topo sensitivity has been found in a
murine fibrosarcoma cell line (Sliutz et al, 1996).
As a complement to ongoing clinical studies the present study
was undertaken to characterize Topo in vitro with respect to
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tumour-type specificity, cross-resistance, schedule-dependency
and possible mechanisms of resistance. This was carried out in a
panel of human tumour cell lines and primary cultures of fresh
human tumour cells from a broad spectrum of diagnoses and by
use ofthe fluorometric microculture cytotoxicity assay (FMCA).
MATERIALS AND METHODS
Cell lines
To evaluate the resistance pattern ofTopo, a human cell line panel
of four sensitive parental cell lines, five drug resistant sublines,
representing different mechanisms of resistance, and one cell line
with primary resistance was used. The cell line panel has been
described in detail previously (Dhar et al, 1996), and the basic
information on each cell line together with references are given in
Table 1. The cell line RPMI 8226/Dox40 shows the classical MDR
phenotype with overexpression of 170 (P-gp). RPMI 8226/LR-5
shows a resistance proposed to be associated with increased levels
of glutathione (GSH), whereas the resistance of U-937-Vcr is
proposed to be tubulin associated. The H69AR cell line expresses
a multidrug-resistant (MDR) phenotype proposed to be mediated
by a multidrug resistance-associated protein (MRP) and the
CEMNVM-l expresses an atypical MDR, which is associated with
altered topoisomerase II (topoll) activity. The exact mechanism of
resistance for the primary resistant ACHN cell line is not known
and may be multifactorial. The resistance patterns of the cell lines
were routinely confirmed in control experiments.
Immunocytochemistry
P-gp and MRP staining was performed on cytocentrifuge cell
preparations with the monoclonal antibodies C219 and QCRL-1
(Centocor, Malvern, PA, USA) fixed in acetone and 70% methanol
respectively, essentially as previously described (Cordell et al,
1984). Briefly, the specimens were incubated at a 1:10 dilution for
2 h at room temperature, followed by washing and application
of a secondary rabbit anti-mouse antibody (Dako, Copenhagen,
Denmark) for 30 min. After washing, a soluble complex of alka-
line phosphatase and a mouse monoclonal anti-alkaline phos-
phatase (APAAP, Dako) was added for 30 min. The slides were
developed using 10 mg ml-' Fast red (Sigma, St Louis, MO, USA)
dissolved in a 0.5 M Tris buffer containing 2 mg ml' Naphtol-
As-Mx-phosphate and 2.4 mg ml' levamisole (Sigma). The
specimens were counterstained with Mayers haematoxylin and
mounted. The fraction oftumour cells expressing positive staining
was estimated after inspection of 100 cells on each slide.
Patient samples
A total of 218 patient tumour samples from the different diag-
noses, detailed in Table 2, were used to determine the activity of
Topo and, for comparison, six other cytotoxic drugs, as detailed
below, chosen to represent different mechanistic classes. However,
because of a limited number ofcells, all drugs could not be tested
in all samples. Thirty solid and 20 haematological tumour samples
and five preparations of normal peripheral blood mononuclear
cells (PBMCs) from healthy blood donors were used to determine
the dose-response relationship for Topo.
The tumour samples were obtained by bone marrow/peripheral
blood sampling, routine surgery or diagnostic biopsy, and this
sampling was approved by the local ethics committee at the
Uppsala University Hospital. Leukaemic cells and PBMCs were
isolated from bone marrow or peripheral blood by 1.077 g ml-
Ficoll-Paque (Kabi-Pharmacia, Uppsala, Sweden) density-
gradient centrifugation (Larsson et al, 1992). Tumour tissue from
solid tumour samples was minced into small pieces and tumour
cells were then isolated by collagenase dispersion followed by
Percoll (Kabi-Pharmacia) density-gradient centrifugation (Csoka
et al, 1994). Cell viability was determined by trypan blue exclu-
sion test and the proportion oftumour cells in the preparation was
judged by inspection of May-Grunwald-Giemsa-stained cytospin
preparations by a cytopathologist. In some cases, cells were cryo-
preserved in a culture medium containing 10% dimethyl-
sulphoxide (DMSO; Sigma) and 50% inactivated fetal calf serum
(FCS; HyClone, Cramlington, UK) by initial freezing for 24 h at
-70°C, followed by storage in liquid nitrogen or at -150°C.
Cryopreservation in this way does not affect drug sensitivity
(Nygren et al, 1992).
Reagents and drugs
Fluorescein diacetate (FDA; Sigma) was dissolved in DMSO and
kept frozen (-20°C) as a stock solution protected from light. A
complete medium consisting of culture medium RPMI-1640
(HyClone) supplemented with 10% inactivated FCS, 2 mm
glutamine, 50 ,ug ml-' streptomycin and 60 jg ml-' penicillin was
used throughout for both cell lines and patient samples.
Both in the cell lines and in the patient samples the activity of
Topo and the standard drugs cisplatin, cytarabine, doxorubicin,
etoposide, melphalan and taxol was determined. Additionally,
camptothecin was tested in the cell lines. In the cell line panel all
drugs were tested at five different drug concentrations, obtained
by tenfold serial dilution from the maximum 100jig ml'. In the
patient samples, the concentrations chosen for the comparisons
Table 1 Resistance factors (Rf) for Topo in cell lines. The resistance factor was defined as the IC50 in the subline divided by that in its parental cell line
Parental cell line Resistant subline Cell type Selecting agent Resistance mechanism References Rffor Topo
CCRF-CEM CEMNM-1 Leukaemia Teniposide Topoll-associated MDR Danks et al (1988) 1.1
NCI-H69 H69AR SCLC Doxorubicin MRP-associated MDR Cole et al (1992) 76.9
RPMI 8226/S 8226/Dox4O Myeloma Doxorubicin Pgp-associated MDR Dalton et al (1986) 1.1
RPMI 8226/S 8226/LR-5 Myeloma Melphalan GSH-associated MDR Mulcahy et al (1994) 0.68
U-937 GTB U-937-Vcr Lymphoma Vincristin Tubulin-associated MDR Botling et al (1994) 1.1
ACHN Renal Primary resistant Nygren and Larsson (1990)
SCLC, small-cell lung cancer; Topoll, topoisomerase 11; MRP, multidrug-resistance protein; P-gp, P-glycoprotein 170; GSH, glutathione.
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were the empirically derived cut-off concentrations (EDCCs),
defined as the concentration that produces a significant scatter of
survival index (SI) values among haematological tumours. This
concentration was used to optimize the conditions for differenti-
ating between sensitive and resistant tumour cell samples. The
concentrations 1 jg ml-' and 0.5 jig ml-' were chosen fortaxol and
Topo respectively and the EDCCs for the other drugs have been
described previously (Larsson et al, 1992). To determine the
dose-response relationship for Topo in patient samples, five
different drug concentrations were used, obtained by a fivefold
serial dilution ofthe drug from 12.5 to 0.02 jig ml-'.
Topo (SmithKline Beecham, King of Prussia, PA, USA) was
dissolved and diluted in sterile water, and camptothecin (Sigma)
was dissolved in methanol-chloroform and diluted further in
phosphate-buffered saline (PBS; HyClone). The other drugs were
obtained from commercial sources and were dissolved according
to guidelines from the manufacturer and further diluted in PBS or
sterile water.
Ninety-six-well microtitre plates (Nunc, Roskilde, Denmark)
were prepared with 20 ,ul per well ofdrug solution at ten times the
desired concentration, with the aid of a programmable pipetting
robot (Propette, Perkin Elmer, Norwalk, CT, USA). The plates
were stored frozen at -70°C for up to 2 months until further use.
Under these conditions, no apparent change in drug activity was
observed (Larsson et al, 1992).
The fluorometric microculture cytotoxicity assay
procedure
The fluorometric microculture cytotoxicity assay (FMCA) is
based on measurement of fluorescence generated from hydrolysis
of FDA to fluorescein by cells with intact plasma membranes and
has been described in detail previously (Larsson et al, 1992).
Briefly, the cells were resuspended in complete medium, and
Table 2 Mean survival index (SI) and response rate to Topo at 0.5 ,ug ml-' for
different diagnoses. Response rate was defined as the fraction of the
samples with SI below the median SI (48%) for cell samples included
Diagnosis Mean SI (SD, %) Response rate (%) n
ALL 49 (26) 53 36
AML 45 (24) 55 43
CLL 20 (20) 94 16
CML 40 (26) 63 6
NHL 26 (19) 94 16
Breast cancer 68 (23) 38 8
Carcinoid 109 (6) 0 4
Colorectal cancer 93 (22) 9 11
NSCLC 69 (29) 19 21
Ovarian carcinoma 58 (29) 40 25
Sarcoma 58 (23) 50 6
Childhood solid tumours 61 (40) 40 5
Assorted tumoursa 66 (36) 43 21
ALL, acute lymphocytic leukaemia; AML, acute myelocytic leukaemia; CLL,
chronic lymphocytic leukaemia; CML, chronic myelocytic leukaemia; NHL,
non Hodgkin's lymphoma; NSCLC, non-small-cell lung cancer. aThe assorted
tumour group includes: adenocortical cancer (three), bladder cancer (three),
renal cell cancer (three), malignant histocytosis (two), small-cell lung cancer
(two), adenocarcinoma (one), choriocarcinoma (one), parotis cancer (one),
phaeochromocytoma (one), malignant melanoma (one), malignant
mesothelioma (one), myeloma (one) and testicular tumour (one).
180-gl cell suspension was seeded into the wells of96-well exper-
imental microtitre plates prepared with drugs as described. Each
drug and concentration was tested in triplicate. Six wells, with
cells but without drugs, served as control and six wells with only
culture medium as blank. The plates were incubated at 37°C for
72 h, followed by aspiration ofthe medium, one wash in PBS and
addition of 100 jl per well ofFDA dissolved in PBS (10 jg ml-').
The plates were incubated for 45 min and the generated fluores-
cence from each well was measured at 538 nm in a 96-well
scanning fluorometer (Fluoroscan II, Labsystems Oy, Helsinki,
Finland). The fluorescence is proportional to the number of viable
cells in the well.
The stability of the drugs over the 72 h incubation at 37°C was
investigated by a bioassay. Plates prepared with the different drugs
were preincubated with 100 gl of medium per well for different
time periods, ranging from 0 to 72 h at 37°C before cell suspension
(RPMI 8226/S) was added. The activity ofthe drugs after different
preincubation times was evaluated, by comparing the SI values
resulting after 72 h incubation and measurement with FMCA as
described above.
Quality criteria for a successful analysis included a fluorescence
signal in the control wells of more than five times mean blank
value, a mean coefficient of variation (CV) in the control wells of
less than 30% and more than 70% tumour cells in the cell prepara-
tion before incubation.
Quantification of FMCA results
Cell survival is presented as survival index (SI), defined as the
fluorescence in experimental wells as a per cent of that in control
wells, with blank values subtracted. The IC50 was defined as the
Topo concentration giving a SI of50%.
For the cell lines, the IC50 values were evaluated for each indi-
vidual cell line and drug with custom-made computer software. A
Delta value was calculated as the logarithm ofthe IC50 ofthe indi-
vidual cell line minus the mean ofall ten logIC50 values (Boyd and
Paul, 1995). The resistance factor for Topo in each subline was
defined as the IC5 ofthe resistant subline divided by theIC50 ofits
sensitive parental cell line.
The IC50 values for the haematological and solid patient samples
respectively were determined graphically from the mean dose-
response curves. Response rate to Topo was defined as the fraction
of samples having a SI below the median SI at 0.5 jig ml-1 for all
samples investigated. The relative effect of a drug on solid and
haematological tumours was indicated by the S/H ratio, defined as
the ratio between the total response rates for the solid and the
haematological samples.
Dependency of Topo activity on dosing schedule and
cell cycle phase
To evaluate the schedule dependency of Topo activity, cells were
exposed to the same AUC (area under the concentration-time
curve) of Topo but during different exposure times. CCRF-CEM
cells and CLL patient cells were used. The cells were exposed to
different Topo concentrations for 8 h, followed by washing with
PBS, addition ofnew culture medium and continuation of incuba-
tion up to 72 h, before performing FMCA. In parallel, cells were
exposed for the doubled concentrations for 4 h, and for four times
the original concentrations for 2 h, before washing the Topo
solution away.
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Figure 1 Effect of Topo in the ten different cell lines as individual dose-response curves for each cell line (A) and expressed as Delta (B). Delta for a cell line
was defined as the log IC50 for the cell line minus the mean of the log IC ,s of all ten cell lines. A deflection to the right and left indicates lower and higher
sensitivity than the mean respectively. C and D show the effect of doxorubicin and camptothecin respectively in the cell line panel. The mean log IC50 was for
Topo -1.23, for doxorubicin -0.25 and for camptothecin -0.09
To examine if the cells were proliferating during the 72 h incu-
bation in the 96-well plates, bromodeoxyuridine (BrdU) incorpo-
ration into cellular DNA was determined with an ELISA kit
from Boehringer Mannheim (Mannheim, Germany) essentially
according to the protocol from the manufacturer. Briefly,
CCRF/CEM cells and CLL patient cells seeded into 96-well plates
were incubated for 72 h together with the pyrimidine analogue
BrdU, which incorporates into DNA of proliferating cells. Then
the cells were fixed and an antibody against BrdU was added. The
immune complex was detected by a substrate reaction using
tetramethylbenzidine (TMB), giving a product that was measured
in a spectrophotometric microplate reader (Dynatech Laboratories,
Billingshurst, UK).
RESULTS
The dose-response curves for Topo in the individual cell lines are
shown in Figure IA. The SCLC cell line NCI-H69 and its subline
H69AR were the most resistant to Topo, together with the renal
carcinoma cell line ACHN. The cell lines ofhaematological origin
were more and equally sensitive, except for the myeloma cell line
RPMI 8226/S with its sublines 8226/Dox40 and 8226/LR-5,
which were of intermediate sensitivity. The experiments were
performed twice with similar results and the mean value was used.
The greatest difference in sensitivity between a cell line and its
subline was seen for NCI-H69 and its MRP-expressing resistant
subline H69AR, where the resistance factor was 77 (Table 1).
Almost no decreased sensitivity compared with parental cell lines
was observed in the sublines with topoIl-, P-gp- and tubulin-asso-
ciated MDR, whereas the 8226/LR-5 subline with GSH-associated
MDR showed a slightly increased sensitivity.
Figure IB-D shows the Delta values, i.e. the deviation of log
IC50 for each cell line from the mean log IC50 ofthe cell line panel,
for Topo (1B) and for comparison for doxorubicin (IC) and camp-
tothecin (ID). Camptothecin showed a sensitivity pattern similar
to that of Topo, the solid tumour- and myeloma cell lines being
more resistant than the haematological ones. Differences between
parental cell line and resistant subline were seen only for NCI-
H69AR and its MRP-expressing subline H69AR, and for RPMI
8226/S and its subline 8226/LR-5 with GSH-mediated resistance.
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A Another pattern was seen for doxorubicin, which was very active
100 against RPMI 8226/S, and which was influenced by all the resis-
tance mechanisms, all the sublines being less sensitive than their
80
parental cell lines.
When examining the immunocytochemical staining of the cell
lines, it was found that the only cell line expressing MRP was
x 60 H69-AR, with 90% of the cells showing positive staining. P-gp
c was highly expressed in the doxorubicin-selected cell line
8226/Dox40 (80% positively stained), but also to a minor extent in
the lymphoma cell lines U937 GTB (50%) and U937-Vcr (60%).
cn Preliminary data indicate that the MRP inhibitor genistein
20 (Verovski et al, 1996) is able to increase the sensitivity for Topo
for the MRP-expressing cell line H69-AR (unpublished data).
The haematological patient samples and the normal PBMCs
0 - showed quite similar Topo sensitivity, with IC50 values of
0 0.01 0.1 1 10 100 66 ng ml-' and 48 ng ml-' respectively, and were more sensitive
than the solid samples in which no IC50 value was obtained (Figure
2). At the highest Topo concentration the SI was 59% in the solid
and 21% in the haematological samples.
In Table 1 the response rates to Topo at 0.5 ,ug ml-1 forthe patient
B samples are listed according to diagnoses. The haematological
100
tumours showed thehighest response rates: 53-94% in thelympho-
cytic leukaemias, 55-63% in the myelocytic leukaemias and 94%
in the non-Hodgkin's lymphomas. Among the solid tumours, the
80 highest response rates were observed in sarcomas (50%), child-
hood solid tumours (40%), ovarian carcinoma (40%) and breast
X 60 cancer (38%). In the assorted tumour group the overall response 60
c \ rate was 43%, with responses seen in small-cell lung cancer (2 out
of2), choriocarcinoma (1 out of 1), malignant mesothelioma (1 out
2 40 of 1), bladder cancer (1 out of 3), adrenocortical carcinoma (1 out
cn) \iof 3) and in the haematological tumours (3 out of 3).
20 The relative effect of the drugs in solid, compared with haema-
tological, tumour samples expressed as the S/H ratio is shown in
Figure 3. Of the six different drugs compared, taxol showed the
0 - greatest relative effect on solid tumours (S/H ratio 1.06), followed
0 0.01 0.1 1 10 100 by cisplatin (0.80), etoposide (0.48) and Topo (0.45). Cytarabine
was the drug with the most pronounced haematological tumour
activity pattern (S/H ratio 0.12).
The correlation coefficients in haematological patient samples
between the SI ofTopo and the SI ofeach ofthe standard cytotoxic
drugs at their EDCCs were compared pairwise and listed in Table 3.
C Topo and taxol showed low correlations with the standard drugs,
100 with coefficients ofcorrelation under 0.3. The coefficients ofcorre-
lation between the other standard drugs were higher and varied
80 between 0.31 and 0.68.
Whencomparing the effect ofTopo afterdifferent exposure times,
a) the longer exposure times gave a better effect than the shorter ones,
_ 60 - \ both in CCRF/CEM and in CLL patient cells (Figure 4A and C).
However, when the test concentrations were compensated for the
40 greater AUC resulting from a longer exposure time, the differences
CD between the different dosing schedules were diminishing, leaving
20 only a very small tendency towards apreference forprolonged expo-
sure (Figure 4B and D). As Topo was shown to be stable under 72 h
FMCA conditions (data not shown), the AUC was calculated as the
0 - Topo concentrationmultipliedby the exposure time.
0 0.01 0.1 1 10 100 The proliferative activity of the CCRF/CEM cells and the CLL
Topotecan conc. (hg ml-1) patient cells in Figure 4. expressed as absorbance at 450 nm per
Topotecan 10 000 seeded cells after a performed proliferation ELISA is
Figure 2 Dose-response relationship forTopo in (A) solid tumours, shown in Figure 5. The CLL patient cells show no proliferation,
(B) haematological tumours and (C) normal peripheral blood mononuclear
cells (PBMCs). Five PBMC preparations, 20 haematological and 30 solid whereas the CCRF/CEM cells show a substantial proliferation,
samples were tested. The bars indicate standard errors ofthe mean which is inhibited in a dose-dependent fashion by Topo.
British Journal ofCancer (1997) 76(2), 211-219 0 CancerResearch Campaign 1997216 EJonsson etal
Taxol
Cisplatin
Toposide
Etopotecan
Doxorubicin
Melphalan
Cytarabine
I-
0 0.2 0.4 0.6
S/H ratio
I
0 1.
0.8 1 1.2
Figure 3 S/H ratios, defined as the ratio between the response rates of solid
and haematological samples, for different drugs at their empirically derived
cut-off concentrations (EDCCs). The number of samples investigated for
Topo was as defined in Table 2, whereas the number of samples for the
standard drugs ranged 96-113 for haematological and 43-89 for solid
tumours
DISCUSSION
The mechanisms of resistance to Topo are not completely under-
stood. Some preclinical cell line data indicate that Topo appears to
be part of the P-gp-mediated multidrug-resistance phenotype, but
the effect of P-gp-mediated transport on Topo accumulation in
cells is substantially smaller compared with classical P-gp
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Figure 5 Proliferation of CEM/S cells (-0-) and primary cultures of CLL cells
from patients (-_-) for 72 h under FMCA conditions in the presence of
different concentrations of Topo. The proliferation is expressed as the
absorbance at 450 nm per 10 000 cells after the ELISA procedure described
in Materials and methods
substrates (Hendricks et al, 1992; Mattem et al, 1993). According
to our findings, the P-gp-mediated resistance does not seem to
influence the effect of Topo to any greater extent. However, the
MRP-expressing cell line H69AR was found to be 77-fold more
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Figure 4 Schedule dependency of the effect of Topo. Dose-response relationship for Topo in CCRF/CEM cells (A and B) and CLL cells (C and D) when
exposing the cells for Topo for 2 (-o--), 4 () and 8 (-A-) h respectively. The exposure expressed as Topo concentration (A and C) and AUC (B and D)
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Table 3 Correlation between the SI values in haematological samples for the indicated drugs at their empirically derived cut-off concentrations (EDCCs). Each
correlation is based on 77-112 data points
Cytarabine Cisplatin Doxorubicin Etoposide Melphalan Taxol
(anti-metabolite) (platinum compound) (DNA intercalator) (topoll inhibitor) (alkylating agent) (tubulin active)
Cisplatin 0.47
Doxorubicin 0.51 0.43
Etoposide 0.31 0.36 0.52
Melphalan 0.44 0.45 0.66 0.68
Taxol 0.26 -0.03 0.22 0.21 0.05
Topotecan 0.23 0.02 0.22 0.10 0.20 0.28
resistant to Topo than the parental cell line, suggesting that MRP
expression may lead to Topo resistance. The pattern of MRP, but
not that ofP-gp, expression also closely paralleled that ofthe resis-
tance factors. The preliminary data pointing to a possibility of
making the resistant cell line H69AR more sensitive to Topo by
adding the MRP inhibitor genistein further indicate a role ofMRP
in Topo resistance. A high degree of cross-resistance to Topo has
been observed by Yang et al (1995) in a mitoxantrone-selected,
P-gp-negative cell line with MRP expression. However, as its
parental cell line showed similarexpression ofMRP, the decreased
Topo accumulation and cytotoxic activity in the resistant cell line
was suggested to be mediated by an unknown mechanism (Yang et
al, 1995). It is not known whether the H69AR cells also have
similar mechanisms operating in addition to MRP.
Investigating the relationship between topoisomerase I and
MRP expression and clinical response to Topo therapy would be a
highly interesting subject for future studies aiming at elucidating
the clinically relevant mechanisms ofresistance.
When comparing the sensitivity pattern of Topo in the cell line
panel with that of its parent compound camptothecin, a similarity
was seen. Topo seems to share the MRP-associated resistance with
its parent compound. On the other hand, doxorubicin showed an
entirely different sensitivity pattern, and was influenced by all the
resistance mechanisms represented in the panel. Comparison of
the sensitivity pattern of different drugs in the cell line panel can
be used to detect mechanistic similarity between compounds (Dhar
et al, 1996). When the drugs were compared in thepatient samples,
very low levels of cross-reactivity were observed between Topo
and standard drugs representing the major types ofmechanisms of
action. The standard drugs correlated substantially more with each
other, and it has been shown previously that drugs from the same
mechanistic classes show even higher correlations (correlation
coefficients > 0.70) (Jonsson etal, 1996). This indicates apotential
role ofTopo in combination therapy.
The activity ofTopo has previously been investigated in clono-
genic assays of freshly explanted specimens from patients with
various solid tumours (Burris et al, 1992). In that study, carci-
nomas ofthe kidney, lung and breast were found to be most sensi-
tive to Topo. Ovarian carcinoma was found to be less sensitive,
giving responses ofthe same magnitude as, forexample, colorectal
cancer. These results contrast to the present results in which renal
cell carcinoma and colorectal tumours were largely insensitive
whereas ovarian carcinoma was sensitive to Topo. The reason for
the apparent discrepancy may at least be related partly to the
different end points used, i.e. proliferation ofclonogenic cells used
in the clonogenic assay and cell death used in the FMCA. If
prediction of tumour regression in vivo is sought, cell kill may
theoretically be a more appropriate and robust end point to
measure. In practice, the correlation with known clinical response
pattern is the most important argument for the validity of any end
point or assay type.
Clinical studies of the anti-tumour activity of Topo have been
performed in a variety oftumor types. In ovarian carcinoma, Topo
has shown promising phase II activity with reported response rates
of around 20% in relapsed patients (Gore et al, 1996). Activity of
Topo has also been reported for NSCLC (Perez-Soler et al, 1996),
SCLC (Ardizzoni et al, 1994; Shiller et al, 1994), soft tissue
sarcoma (Eisenhauer et al, 1994) and breast cancer (Chang et al,
1995). In renal cell cancer (Ilson et al, 1993; Law et al, 1994) and
colorectal cancer (Sugarman et al, 1994) the drug appears inactive.
Little phase II experience has been reported for haematological
tumours, although responses in phase I trials have been observed
in patients with relapsed or refractory acute leukaemia (Kantarjian
et al, 1993; Rowinsky et al, 1994).
The present 'in vitro phase II' results using cell kill as end point
appears therefore to be more in accordance with the reported clin-
ical activity than the clonogenic assay. As for the majority of
currently used chemotherapeutic drugs, Topo showed a high
degree of differential activity against haematological tumours in
the present study. The present results indicate that in addition
to various haematological tumours sarcomas, childhood solid
tumours and breast cancer may be suitable targets for clinical
phase II studies.
The in vitro effect of Topo has previously been shown to be
dependent on the exposure time, with longer incubations being
more active than shorter ones (Burris etal, 1992; Cheng et al, 1994;
Uckun et al, 1995). However, the drug effects were not adjusted for
the total exposures precluding any firm conclusions about superi-
ority for protracted scheduling (true 'time dependency'). In the
present study, the apparent time dependency of the effect on both
CCRF-CEM and CLL patient cells was largely abolished when
adjustments for in vitro exposure was made. Thus, for the different
exposure times tested in the present study, the drug effects were
best explained by the area under the concentration-time curve
(AUC). Furthermore, Topo was clearly highly active against
patient CLL cells showing no evidence of DNA synthesis during
the 72-h assay period, strongly arguing against a requirement for
S-phase progression, at least for this cell type.
In vivo, however, the question ofdosing schedule dependency is
more complicated and involves both pharmacokinetic factors and
the toxic effects on normal host cells. A single optimal schedule
could not be determined from the early preclinical in vivo studies
(Dancey and Eisenhauer, 1996), although support for protracted
schedules was obtained from some tumour model systems
(Houghton et al, 1992). Nevertheless, the most commonly used
clinical phase II schedule, a daily x five schedule, has been
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compared with more protracted schedules without any apparent
advantage ofthe latter (Dancey and Eisenhauer, 1996). This clinical
experience and the present results may thus suggest that the optimal
schedule forTopo is yet to be defined fordifferent tumour types and
that additional short-term schedules might be explored. In this
context it should be noted that, also from a theoretical point ofview,
AUC vs time dependency for drugs with short half-lives may vary
depending on the sensitivity ofthe tumour model system used, irre-
spective ofcell cycle phase specificity (Karlsson et al, 1996).
We have previously shown that the FMCA can detect tumour-
type specific activity retrospectively for a series of standard drugs
(Nygren et al, 1994) and prospectively for early phase I-LI drugs
such as 2-chlorodeoxyadenosine (Larsson et al, 1994), gem-
citabine (Csoka et al, 1995) and taxol (Nygren et al, 1995). The
use of a human cell line panel can contribute with information on
resistance mechanisms and on mechanistic similarity to other stan-
dard and investigational agents (Dhar et al, 1996). The parallel or
sequential application of these model systems may provide impor-
tant initial information on selectivity and similarity of novel anti-
cancer drugs.
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